Claims
- 1-37. (cancelled).
- 38. A preformed porous ceramic carrier comprising an Interconnected skeleton having pores the majority of which are in the range of from about 20 to about 800 micron, the carrier having a density of less than about 40% theoretical, the pores containing a second material deposited therein, the rate of release of the second material from the carrier being controlled.
- 39. A carrier according to claim 38, wherein the skeleton is made up of scaffolding and struts.
- 40. A carrier according to claim 38, wherein the skeleton has average pore sizes in the range of 20 to 800 micron.
- 41. A carrier according to claim 40, wherein the average pore size is in the range of 60 to 800 micron.
- 42. A carrier according to claim 41, wherein the micropores were formed by sintering a precursor of the carrier under conditions which were below those required for full sintering.
- 43. A carrier according to claim 38, wherein the skeleton is formed of a biocompatible material.
- 44. A carrier according to claim 38, wherein the density ranges from about 10% to about 30% of theoretical density.
- 45. A carrier according to claim 38, wherein the pores contain any one or more of: growth factors; antibiotics; vitamins; proteins; hormones; a chemotherapy agent; or a radio opacifying agent, or the like.
- 46. A carrier according to claim 45, wherein the pores containing any or more of the following growth factors:
a bone growth material FGF (fibroplast growth factor) IGF-I IGF-II PDGF (platelet derived growth factor) TGF-B (transforming growth factor) a bone forming or bone degrading cell. BMP-Z HGH concentrations of human derived growth factors
- 47. A carrier according to claim 45, wherein the chemotherapy agent is Cisplatin.
- 48. A carrier according to claim 45, wherein the radio opacifying agent is strontium −67 or samarium −153.
- 49. A carrier according to claim 45, wherein the agent is MTX.
- 50. A carrier according to claim 38, wherein the pores contain one or more of Werner-type co-ordination complexes; macrocylic complexes; metallocenes and sandwich complexes and organometallics.
- 51. A carrier according to claim 38, wherein the surface of the pores has been modified to control release of the second material.
- 52. A carrier according to claim 51, wherein the surface of the pores has been modified by treatment with acid or alkali or plasma or chemical vapour deposition.
- 53. A carrier according to claim 38, wherein the pores contain the second material in a degradable support, e.g. a biodegradable support.
- 54. A carrier according to claim 53, wherein the biodegradable support is a collagen or polymer.
- 55. A carrier according to claim 53, wherein the support is PCPP.SA, PCC, CPP.SA, FAD-SAPTMC, PM.
- 56. A carrier according to claim 53, wherein the pores contain layers of second material and biodegradable support, each layer being different from its neighbour or neighbours.
- 57. A carrier according to claim 53, wherein the pores contain material in, layers, arranged as alternating layers of agent-free layer and of agent-containing layers or by the concentration of agent across different layers of collagen or polymer.
- 58. A carrier according to claim 38, wherein the carrier has a degree of reticulation high enough to reduce the pressure gradient generated in infiltration of the second material into the pores of the carrier.
- 59. A carrier according to claim 38, wherein the second material is introduced into the pores by one or more of a centrifugation, immersion, vacuum impregnation or freeze drying technique.
- 60. A carrier according to claim 38, wherein the exterior surface thereof has been coated with a biodegradable polymer containing a drug.
- 61. A carrier according to claim 38, wherein the skeleton of the ceramic carrier is formed from a metal or non-metal oxide or the like.
- 62. A carrier according to claim 61, wherein the ceramic skeleton is partially or fully resorbable.
- 63. A carrier according to claim 62, wherein the skeleton is formed of calcium phosphate hydroxyapatite.
- 64. A preformed porous ceramic carrier comprising an interconnected skeleton having pores the majority of which are in the range of from about 20 to about 1000 micron, the carrier having a density of less than about 40% theoretical, the pores containing MTX, the rate of release of the MTX from the pores being controlled.
- 65. A carrier according to claim 64, wherein the MTX has been loaded into the pores by centrifugation and/or freeze drying.
- 66. A preformed ceramic carrier comprising an interconnected skeleton having pores the majority of which are in the range of from about 20 to about 1000 micron, the carrier having a density of less than about 40% theoretical, the pores containing Fe(phen)3[ClO4]2 the rate of release of the Fe(phen)3[ClO4]2 being controlled.
- 67. A carrier according to claim 66, wherein the Fe(phen)3[ClO4]2 has been loaded into the pores by vacuum impregnation.
- 68. A preformed porous ceramic carrier comprising an interconnected skeleton having pores the majority of which are in the range of from about 20 to about 1000 micron, the carrier having a density of less than about 40% theoretical, the pores containing Fe(phen)3[ClO4]2 and a glycolide, the rate of release of Fe(phen)3[ClO4]2.
- 69. A preformed porous ceramic carrier comprising an interconnected skeleton having pores the majority of which are in the range of from about 20 to about 1000 micron, the carrier having a density of less than about 40% theoretical, the pores containing Cisplatin, the rate of release of the Cisplatin being controlled.
- 70. A preformed porous ceramic carrier comprising an interconnected skeleton having pores the majority of which are in the range of from about 20 to about 1000 micron, the carrier having a density of less than about 40% theoretical, the pores containing Cisplatin and a glycolide, the rate of release of the Cisplatin and a glycolide being controlled.
- 71. A preformed porous ceramic comprising an interconnected skeleton having pores the majority of which are in the range of from about 20 to about 1000 micron, the carrier having a density of less than about 40% theoretical, the pores containing prednisolone, the rate of release of the prednisolone being controlled.
- 72. A carrier according to claim 38, shaped for orthopaedic, maxillo-facial, or cranio-facial replacement.
- 73. A carrier according to claim 38, shaped for location at an intramuscular site, interperitoneal site, subcutaneous site, central nervous system or occular site.
- 74. A carrier according to claim 38, wherein the pores contain a general chemical or resin or petroleum derivative or explosives.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0020610.2 |
Aug 2000 |
GB |
|
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This is a Continuation Application of U.S. application Ser. No. 10/362,314, entitled Use of a Porous Carrier, filed on Feb. 20, 2003, now pending, which is based on International Application Serial Number PCT/GB01/03739, entitled Use of a Porous Carrier, filed on Aug. 21, 2001, which claims priority to GB 0020610.2, entitled Use of Porous Carrier, filed Aug. 21, 2000.
Continuations (1)
|
Number |
Date |
Country |
Parent |
10362314 |
|
US |
Child |
10728006 |
Dec 2003 |
US |